GSK has agreed to acquire biopharmaceutical company 35Pharma for $950 million.
35Pharma is a Canada-based biopharmaceutical company conducting clinical trials, the British drugmaker announced Wednesday. The acquisition includes the therapeutic HS235, which is aimed at treating cardiopulmonary diseases.
The GSK share was temporarily trading 0.56 percent higher at GBP 22.13 in London.
DJG/DJN/sha/kla
DOW JONES
By the way: GSK and other US stocks can even be traded on finanzen.net ZERO until 11 p.m. (without order fees, plus spreads). Open a depot now for free and secure a new customer bonus!
Selected leveraged products on GSK
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on GSK
The leverage must be between 2 and 20
Advertising